<- Go Home
Carmat SA
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Market Cap
EUR 36.6M
Volume
92.2K
Cash and Equivalents
EUR 11.4M
EBITDA
-EUR 50.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-EUR 43.5M
Profit Margin
628.37%
52 Week High
EUR 4.50
52 Week Low
EUR 0.69
Dividend
N/A
Price / Book Value
-1.28
Price / Earnings
-0.54
Price / Tangible Book Value
-1.28
Enterprise Value
EUR 83.7M
Enterprise Value / EBITDA
-1.67
Operating Income
-EUR 52.0M
Return on Equity
341.29%
Return on Assets
-54.82
Cash and Short Term Investments
EUR 11.4M
Debt
EUR 58.5M
Equity
-EUR 22.5M
Revenue
EUR 6.9M
Unlevered FCF
-EUR 32.3M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium